With painkiller addiction on the rise.

On 23 June, only a few days following the Oxecta approval, the FDA rejected Remoxy due to manufacturing problems. Remi Barbier, president and ceo of Discomfort Therapeutics in Austin, Texas, which developed the drug with Pfizer, says the firms are working to resolve those issues now.) Picture: by Flickr user Be.Futureproof under Innovative Commons.. With painkiller addiction on the rise, drugmakers have come up with clever methods to discourage such behavior. As recently as 20 June, the US Food and Medication Administration approved a fresh abuse-deterrent formulation of oxycodone called Oxecta, produced by Pfizer and Acura Pharmaceuticals of Palatine, Illinois.Panos Kontzalis was appointed as Chief Executive Officer and Director, Dr. Alexandre Vamvakides became Chief Scientific Director and Officer, and ANAVEX added a distinguished, medically trained MBA to its Table of Directors. The company attracted prominent researchers Dr. Jean Jacques Dr and Bourguignon. Tangui Nicolas Maurice, who joined up with the company’s scientific team and had been appointed as users of the scientific committee. Dr. Kontzalis is definitely a 38-yr pharmaceutical-sector veteran.